

*Amendments to the Claims*

Claims 1-113 (cancelled)

Claim 114 (currently amended): An isolated peptide less than 15 amino acids in length comprising a peptide consisting of the sequence ~~an oligopeptide selected from the group~~ consisting of:

~~HSFPHPV (SEQ ID NO:92)~~

~~ALGTTCTYA (SEQ ID NO:6853)~~

VLAKELKFV (SEQ ID NO:6827)

~~ILLWQPPV (SEQ ID NO:6834)~~

~~IMYSAIDTTV (SEQ ID NO:6836) and~~

~~LLFTWLDRSV (SEQ ID NO:6825).~~

Claims 115-120 (cancelled)

Claim 121 (previously added): The peptide of claim 114 which is 11 amino acids in length.

Claim 122 (previously added): The peptide of claim 114 which is 10 amino acids in length.

Claim 123 (previously added): The peptide of claim 114 which is 9 amino acids in

length.

Claim 124 (currently amended): The peptide of claim 114, which is fused to a T helper peptide.

Claim 125 (previously added): The peptide of claim 114, which is fused to spacer or linker amino acids.

Claim 126 (previously added): The peptide of claim 114, which is fused to a carrier.

Claim 127 (previously added): The peptide of claim 114, which is linked to a lipid.

Claim 128 (previously added): A fusion protein comprising the peptide of claim 114.

Claim 129 (previously added): A homopolymer of the peptide of claim 114.

Claim 130 (previously amended): A heteropolymer of the peptide of claim 114 and different peptides.

Claim 131 (previously added): A composition comprising the peptide of claim 114 and a carrier.

Claim 132 (cancelled)

Claim 133 (previously added): A composition comprising the peptide of claim 114 and a liposome.

Claim 134 (currently amended): A composition comprising the peptide of claim ~~114~~ 117 and a pharmaceutically acceptable carrier.

Claim 135 (currently amended): A composition comprising the peptide of claim 114, and one or more ~~second~~ other peptides.

Claim 136 (previously added): The composition of claim 135, wherein said peptides form a fusion protein.

Claim 137 (previously added): The composition of claim 135, which comprises a carrier.

Claim 138 (cancelled)

Claim 139 (previously added): The composition of claim 135, wherein said peptides are fused by spacer or linker amino acids.

Claim 140 (previously added) The composition of claim 135, which comprises a pharmaceutically acceptable carrier.

Claims 141-214 (cancelled)

Claim 215 (currently amended): The peptide of claim ~~124~~ 214, wherein the T helper peptide is a PADRE®-universal T-helper-cell pan-DR-binding epitope.

Claims 216-229 (cancelled)

Claim 230 (new): The peptide of claim 215, wherein the pan-DR-binding epitope comprises the amino acid sequence of SEQ ID NO:6698.







